Structure Therapeutics (GPCR) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

GPCR Structure Therapeutics

Watchlist

43.160
+0.970+2.30%

Trading Oct 2 11:27 ET

2.47BMarket Cap-24592P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
Seeking AlphaOct 1 10:22 ET
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
Seeking AlphaSep 30 11:25 ET
GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer
PR NewswireSep 30 07:00 ET
Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now?
Yahoo FinanceSep 29 02:05 ET
21 Stocks to Play a 'Magical Moment' In Healthcare
Barron'sSep 27 21:30 ET
21 Stocks to Play a 'Magical Moment' in Healthcare -- Barrons.com
Barron'sSep 27 15:24 ET

Comments

104266827

Sep 23 07:37

still uptrend..go buy target price $65

Share Your Profit/Loss

Jensen 108

Sep 13 11:34

this one so hard to achieve 10% above. profit taken first.

Share Your Profit/Loss

Jensen 108

Aug 13 09:44

$Structure Therapeutics (GPCR.US)$ hopefully the uptrend continues

Meltyy

Jul 17 22:40

Smid-cap obesity stocks hit by $RHHBY positive Ph1 data for oral GLP-1 obesity drug ⚠️

$ROCHE HOLDING AG (RHHBY.US)$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$ $Structure Therapeutics (GPCR.US)$ $Viking Therapeutics (VKTX.US)$ $Lipocine (LPCN.US)$

frankinglily

Jul 12 03:26

Is the diet pill market too profitable to lose?

Why do you think $Pfizer (PFE.US)$ decided to progress with Danuglipron? (Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co (LLY.US)$ Orforglipron and $Structure Therapeutics (GPCR.US)$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA